TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04208373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ 64417184 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ 64417184 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: etravirine tables will be administered orally.
Study: NCT04799782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: 15 mg dose before bed-time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill before bed-time
Study: NCT02457897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Oral supplement given every 8 hours
Study: NCT03445039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional TSFE
Description: The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional TSFE
Description: The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone grafting materials
Description: The bone substitute is placed into the siuns under the membrane before the implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone grafting materials
Description: The bone substitute is placed into the siuns under the membrane before the implant placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSFE by DASK drills
Description: The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
Study: NCT03445039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSFE by DASK drills
Description: The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without bone grafting materials
Description: The bone substitute will not be placed into the sinus before the implant placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without bone grafting materials
Description: The bone substitute will not be placed into the sinus before the implant placement.
Study: NCT00399802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZA
Description: Single ZA 4 mg IV infusion at the start of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Once-daily odanacatib 5 mg tablet for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Odanacatib matching placebo
Description: Once-daily odanacatib matching placebo for 4 weeks
Study: NCT03568058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
Study: NCT00399802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZA matching placebo
Description: Single IV infusion of ZA matching placebo given at the start of treatment
Study: NCT04689022

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mississippi Scale for Combat-Related PTSD (M-PTSD)
Description: The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mississippi Scale for Combat-Related PTSD (M-PTSD)
Description: The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: visual analogue scale (VAS)
Description: pain intensity

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: visual analogue scale (VAS)
Description: pain intensity

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: visual analogue scale (VAS)
Description: pain intensity

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Douleur Neuropathique 4 questions (DN4)
Description: neuropathic pain component

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Douleur Neuropathique 4 questions (DN4)
Description: neuropathic pain component

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Douleur Neuropathique 4 questions (DN4)
Description: neuropathic pain component
Study: NCT02959138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib.
Description: 20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib.
Description: 20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib.
Description: 20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
Study: NCT02391038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 IV.
Study: NCT03401177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo is used, to provide a control to the active group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy resistance training
Description: Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heavy resistance training
Description: Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
Study: NCT02366208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Tα1
Description: 1.6 mg/ml, once a week, taken subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match PEG-Tα1
Description: 1ml, once a week, taken subcutaneously
Study: NCT03134963

Intervention type: OTHER
Intervention: Transcranial doppler ultrasonography
Description: Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.

Intervention type: OTHER
Intervention: Transcranial doppler ultrasonography
Description: Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.

Intervention type: OTHER
Intervention: Transcranial doppler ultrasonography
Description: Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.

Intervention type: OTHER
Intervention: Transcranial doppler ultrasonography
Description: Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.

Intervention type: OTHER
Intervention: Blood pressure monitoring
Description: Continuous blood pressure recording

Intervention type: OTHER
Intervention: Blood pressure monitoring
Description: Continuous blood pressure recording
Study: NCT02366208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: 10 mg, once daily, taken orally for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adefovir
Description: 10 mg, once daily, taken orally for 48 weeks
Study: NCT00680303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Lidcombe Program for early stuttering

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Lidcombe Program for early stuttering

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Lidcombe Program for early stuttering
Study: NCT00632710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy placebo
Description: disconnected laser (same device - experimental group)
Study: NCT01755689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm.
Study: NCT02449577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ABCD
Description: Participants receive test beverages in the randomised order ABCD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence CADB
Description: Participants receive test beverages in the randomised order CADB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DACB
Description: Participants receive test beverages in the randomised order DACB
Study: NCT01755689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Description: Three doses administered intramuscularly (IM) in the deltoid of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Description: Three doses administered intramuscularly (IM) in the deltoid of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Description: Three doses administered intramuscularly (IM) in the deltoid of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Description: Three doses administered intramuscularly (IM) in the deltoid of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Description: Three doses administered intramuscularly (IM) in the deltoid of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the deltoid of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the deltoid of the left arm.
Study: NCT02449577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence CBAD
Description: Participants receive test beverages in the randomised order CBAD
Study: NCT05793710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The principle of laughter plus Qigong
Description: The intervention program include muscle stretching, breathing exercises, and closing exercises. The laughing practice method begins with a warm-up consisting of laughing to stretch the body, yawning, and exerting the voice, and ends with expelling all the qi in order to return to natural movements and return to taking care of your body and mind (He et al., 2021).~The LQP program meets once a week for 90 minutes and runs for 12 weeks. The program content: the laughter skills were 50-60 minutes, the feedback was 30 minutes, and relaxation was 10 minutes.
Study: NCT03134963

Intervention type: OTHER
Intervention: Blood pressure monitoring
Description: Continuous blood pressure recording

Intervention type: OTHER
Intervention: Blood pressure monitoring
Description: Continuous blood pressure recording

Intervention type: OTHER
Intervention: Heart rate monitoring
Description: Continuous heart rate monitoring

Intervention type: OTHER
Intervention: Heart rate monitoring
Description: Continuous heart rate monitoring

Intervention type: OTHER
Intervention: Heart rate monitoring
Description: Continuous heart rate monitoring

Intervention type: OTHER
Intervention: Heart rate monitoring
Description: Continuous heart rate monitoring
Study: NCT01349010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: 250mg (1 tablet) bid. p.o for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet bid. p.o for 8 weeks
Study: NCT04055506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg
Study: NCT03325335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam premedication
Description: Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
Study: NCT03134963

Intervention type: OTHER
Intervention: End tidal CO2 monitoring
Description: Continuous ETCO2 monitoring

Intervention type: OTHER
Intervention: End tidal CO2 monitoring
Description: Continuous ETCO2 monitoring

Intervention type: OTHER
Intervention: End tidal CO2 monitoring
Description: Continuous ETCO2 monitoring

Intervention type: OTHER
Intervention: End tidal CO2 monitoring
Description: Continuous ETCO2 monitoring
Study: NCT03325335

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil infusion
Description: Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
Study: NCT03134963

Intervention type: OTHER
Intervention: Addenbrooke's cognitive examination
Description: Performance of a memory test

Intervention type: OTHER
Intervention: Addenbrooke's cognitive examination
Description: Performance of a memory test

Intervention type: OTHER
Intervention: Addenbrooke's cognitive examination
Description: Performance of a memory test

Intervention type: OTHER
Intervention: Addenbrooke's cognitive examination
Description: Performance of a memory test
Study: NCT04813679

Intervention type: DIAGNOSTIC_TEST
Intervention: Bed side Ultrasound Sonography
Description: Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha

Intervention type: DIAGNOSTIC_TEST
Intervention: Bed side Ultrasound Sonography
Description: Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
Study: NCT03340493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg and 0.4mg/kg are being used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
Study: NCT01883583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Ultrasound And Sonoelastography
Description: Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
Study: NCT01848444

Intervention type: OTHER
Intervention: Breastmilk
Description: to measure levels of contaminants in human breastmilk samples
Study: NCT01556919

Intervention type: PROCEDURE
Intervention: Standard of care endoscopy
Description: standard of care endoscopy
Study: NCT03325335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol infusion
Description: Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
Study: NCT02449577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ABDC
Description: Participants receive test beverages in the randomised order ABDC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DABC
Description: Participants receive test beverages in the randomised order DABC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DCAB
Description: Participants receive test beverages in the randomised order DCAB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DBCA
Description: Participants receive test beverages in the randomised order BDCA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ADCB
Description: Participants receive test beverages in the randomised order ADCB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence BADC
Description: Participants receive test beverages in the randomised order BADC
Study: NCT03325335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion
Description: Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
Study: NCT01541254

Intervention type: DEVICE
Group type: OTHER
Intervention: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
Description: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
Study: NCT01022853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: intravenous each 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: oral continuously
Study: NCT01463774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Canagliflozin tablet
Description: Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Canagliflozin tablet
Description: Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Metformin IR tablets
Description: Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Metformin IR tablets
Description: Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Canagliflozin/metformin fixed dose combination tablets
Description: Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Canagliflozin/metformin fixed dose combination tablets
Description: Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
Study: NCT04762173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Description: Access to two online, self-guided programs available on the SilverCloud Health website.
Study: NCT03873350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of kombucha
Description: The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Consumption of heat-sterilized kombucha
Description: The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
Study: NCT04045223

Intervention type: OTHER
Intervention: Blood samples
Description: Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.

Intervention type: OTHER
Intervention: Blood samples
Description: Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.

Intervention type: OTHER
Intervention: Blood samples
Description: Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
Study: NCT02634164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine Supplement
Description: For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoleucine Supplement
Description: For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine Supplement combined with Isoleucine Supplement
Description: For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.